RVMD.NASDAQRevolution Medicines, INC

Form 4: Revolution Medicines Executive Sells Shares to Cover Tax Obligations

Sentiment:

SEC Form 4

📋All filings for Revolution Medicines, INC
🔒Login to Follow

Stephen Michael Kelsey, President of Research and Development at Revolution Medicines, sold 4,663 shares of common stock on December 16, 2024, to cover tax obligations related to vesting restricted stock units.

Summary

  • Stephen Michael Kelsey, President of Research and Development at Revolution Medicines, sold 4,663 shares of common stock on December 16, 2024.
  • The sale was executed at a price of $45.4038 per share.
  • The transaction was made pursuant to a Rule 10b5-1 trading plan adopted on May 31, 2023.
  • The purpose of the sale was to satisfy the reporting person's tax withholding obligation upon the vesting of restricted stock units (RSUs) after July 15, 2023.
  • Following the transaction, Kelsey beneficially owns 259,745 shares of common stock, including 77,326 RSUs.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The document simply reports a routine stock sale by an executive to cover tax obligations. It doesn't indicate any positive or negative developments for the company.

Industry Context

Sales of shares by company executives are a normal part of corporate governance. Often these sales are pre-planned to avoid any accusations of insider trading. It is common for executives to sell shares to cover tax obligations.

Key Dates

DateDescription
May 31, 2023Date of adoption of Rule 10b5-1 trading plan.
July 15, 2023Start date for RSUs vesting after this date.
December 16, 2024Date of the stock sale transaction.
December 18, 2024Date of signature for the Form 4 filing.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.